Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SSY Group ( (HK:2005) ) just unveiled an announcement.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two drugs: Diprophylline Injection and Formoterol Fumarate Inhalation Solution. These approvals enhance the company’s portfolio in respiratory treatments, potentially strengthening its market position and offering new options for patients with conditions like asthma and COPD.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating treatments for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
YTD Price Performance: -20.41%
Average Trading Volume: 13,076,849
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.12B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.